These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19303027)

  • 1. X-ray crystallography of chemical compounds.
    Deschamps JR
    Life Sci; 2010 Apr; 86(15-16):585-9. PubMed ID: 19303027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using X-ray crystallography in drug discovery.
    Rowland RS
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):613-9. PubMed ID: 12197319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystallographic fragment screening.
    Badger J
    Methods Mol Biol; 2012; 841():161-77. PubMed ID: 22222452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The critical role of QM/MM X-ray refinement and accurate tautomer/protomer determination in structure-based drug design.
    Borbulevych OY; Martin RI; Westerhoff LM
    J Comput Aided Mol Des; 2021 Apr; 35(4):433-451. PubMed ID: 33108589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structures of drugs: advances in determination, prediction and engineering.
    Datta S; Grant DJ
    Nat Rev Drug Discov; 2004 Jan; 3(1):42-57. PubMed ID: 14708020
    [No Abstract]   [Full Text] [Related]  

  • 6. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The determination of crystal structures of active pharmaceutical ingredients from X-ray powder diffraction data: a brief, practical introduction, with fexofenadine hydrochloride as example.
    Brüning J; Schmidt MU
    J Pharm Pharmacol; 2015 Jun; 67(6):773-81. PubMed ID: 25677117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. X-ray crystallography over the past decade for novel drug discovery - where are we heading next?
    Zheng H; Handing KB; Zimmerman MD; Shabalin IG; Almo SC; Minor W
    Expert Opin Drug Discov; 2015; 10(9):975-89. PubMed ID: 26177814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of soluble and membrane protein structures by X-ray crystallography.
    Lieberman RL; Peek ME; Watkins JD
    Methods Mol Biol; 2013; 955():475-93. PubMed ID: 23132076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automated crystal mounting and data collection for protein crystallography.
    Muchmore SW; Olson J; Jones R; Pan J; Blum M; Greer J; Merrick SM; Magdalinos P; Nienaber VL
    Structure; 2000 Dec; 8(12):R243-6. PubMed ID: 11188700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystallization to obtain protein-ligand complexes for structure-aided drug design.
    Danley DE
    Acta Crystallogr D Biol Crystallogr; 2006 Jun; 62(Pt 6):569-75. PubMed ID: 16699182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?
    Almarsson O; Zaworotko MJ
    Chem Commun (Camb); 2004 Sep; (17):1889-96. PubMed ID: 15340589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diamond: shedding light on structure-based drug discovery.
    Brown DG; Shotton EJ
    Philos Trans A Math Phys Eng Sci; 2015 Mar; 373(2036):. PubMed ID: 25624512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical considerations for the qualitative and quantitative determination of process-induced disorder in crystalline solids.
    Newman A; Zografi G
    J Pharm Sci; 2014 Sep; 103(9):2595-2604. PubMed ID: 24623166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. X-ray crystallography of DNA-drug complexes.
    Peek ME; Williams LD
    Methods Enzymol; 2001; 340():282-90. PubMed ID: 11494854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography.
    Ishchenko A; Cherezov V; Liu W
    J Vis Exp; 2016 Sep; (115):. PubMed ID: 27683972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal polymorphism in chemical process development.
    Lee AY; Erdemir D; Myerson AS
    Annu Rev Chem Biomol Eng; 2011; 2():259-80. PubMed ID: 22432619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal morphologies and polymorphs in tolbutamide microcrystalline powder.
    Li Destri G; Marrazzo A; Rescifina A; Punzo F
    J Pharm Sci; 2013 Jan; 102(1):73-83. PubMed ID: 23042550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of crystallography in drug design.
    Deschamps JR
    AAPS J; 2005 Dec; 7(4):E813-9. PubMed ID: 16594633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Practical Approach to Protein Crystallography.
    Ilari A; Savino C
    Methods Mol Biol; 2017; 1525():47-78. PubMed ID: 27896717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.